The Priority Review

Tag

KRAS

1 story

  1. Clinical trials

    DelveInsight reports KRAS inhibitors market to grow positively by 2036

    DelveInsight said the total KRAS inhibitors market size is expected to grow positively by 2036, driven by therapies such as Divarasib (RG6330), Olomorasib (LY3537982) and MK-1084. The company noted the United States accounted for the largest market share in 2025, with 539,400 incident NSCLC cases.